-
2023-509331-83-00
5
2021-07-28
complement 3 glomerulopathy
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2025-522542-40-00
5
2026-06-19
Acute Ischemic Stroke
-
2025-523461-17-01
5
2026-06-01
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus
-
2025-522705-37-00
4
2026-04-21
HIDRADENITIS SUPPURATIVA
-
2024-513174-22-00
4
2026-04-14
Atrophic Age-related Macular Degeneration (AMD)
-
2025-522544-40-00
5
2026-03-27
Hereditary transthyretin-mediated amyloidosis with polyneuropathy
-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2025-521416-19-00
4
2026-03-12
Recurrence of Clostridioides difficile Infection
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-520253-21-00
5
2026-02-02
Chronic Kidney Disease
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2025-521242-26-00
4
2025-11-27
Moderately to Severely Active Ulcerative Colitis
-
2024-519976-19-00
5
2025-11-26
Asthma with type 2 inflammation characterized by an eosinophilic pheno
-
2025-520555-89-00
5
2025-11-14
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-519345-30-00
5
2025-11-12
IgA nephropathy
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca